Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and SHR-8068 with Chemoradiotherapy in Rectal Cancer
NCT07454720Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Mar 2026
- Primary completion
- Nov 2032
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of adebrelimab and CS1002 in rectal cancer (3 cohorts), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Pathological Complete Response at 12 months. Started Mar 2026; status: recruiting.
02
Drugs
adebrelimabCS1002
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07454720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454720.